I guess my question for the Minister is: can we expect to see something, even within acknowledging health is a challenging area, but with the Pharmac aspect in terms of a cluster, because I think the reality of cost-benefit payback and benefit not just being financial but other aspects, of course—around social, particularly—is significant in the pharmaceutical space. When you weigh it up in terms of dollar for dollar for, say, road safety versus pharmaceutical and the benefit derived, pharmaceuticals will trump most other elements nine times out of 10. So that's the first aspect.